Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Shery Mounir William Labib

Shery Mounir William Labib

Skin Klinic, Egypt

Title: Intra-lesional methotrexate in dermatology with highlight on intra-lesional Methotrexate in treatment of hypertrophic scars and keloids

Biography

Biography: Shery Mounir William Labib

Abstract

Methotrexate is an immunosuppressive agent that acts as a folic acid analog which competitively inhibits dihydrofolate reductase enzyme. Methotrexate comes after Prednisolone as one of the most commonly prescribed systemic drugs in dermatology. Methotrexate as an intra-lesional drug was used in treatment of skin tumors as cutaneous squamous cell carcinoma and keratoacanthoma with satisfactory results. Also, several studies used intra-lesional methotrexate (IL-MTX) in treatment of hypertrophic scars/keloids either alone or as an adjuvant to surgery. In addition nail psoriasis was successfully treated with IL-MTX. Same as systemic MTX intake, pre-treatment investigations must be done (complete blood count, liver and kidney function tests and pregnancy test) to exclude any hematological abnormalities, renal insufficiency and risks of hepatotoxicity. For hypertrophic scars and keloids, IL-MTX not only improves thickness and flexibility of scar tissue but also decrease vascularity which results in better functional, aesthetic and psychological impact on the patient. Using IL-MTX is a good treatment modality in treating various skin tumors. It is very promising in hypertrophic scars and keloids. However, more studies are needed to standardize its use.